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Prevalence of latent prostate cancer and prostatic intraepithelial
neoplasia in İstanbul, Turkey: an autopsy study
Nusret AKPOLAT1, Yalçın BÜYÜK2, İbrahim UZUN2, İlhan GEÇİT3, Gülay KURNAZ2

Aim: To investigate the frequency of latent prostatic carcinoma (PCa) and prostatic intraepithelial neoplasia (PIN) in
the Turkish population.
Materials and methods: PCa and PIN were evaluated in 116 male autopsy cases in which the cause of death was
nontumoral. All patients were Turkish, living in İstanbul, and aged 40-79 years.
Results: The prevalence of PCa was 19.8% and the decade rates (decades 5-8) were 9.5%, 12.5%, 18.8%, and 37%,
respectively (P < 0.011). The rates of high-grade prostatic intraepithelial neoplasia (HGPIN) were 33.3%, 31.3%, 56.3%,
and 25.9% for decades 5-8, respectively (P > 0.05). A total of 68.4% of PCa cases were HGPIN. There was a statistically
significant correlation among HGPIN, PCa, and Gleason scores (P < 0.002).
Conclusion: The prevalence of latent PCa in the Turkish population is very high (19.7%). In order to determine latent
PCa cases, males over 40 years of age must be screened more strictly.
Key words: Prostate cancer, prostatic intraepithelial neoplasia, prevalence, Turkish males, autopsy

Türkiye, İstanbul’da latent prostat kanseri ve prostatik intraepitelyal neoplazinin
sıklığı: Otopsi çalışması
Amaç: Türk toplumunda latent prostat kanseri (PCa) ve prostatic intraepitelyal neoplazi (PIN) sıklığını araştırmayı
amaçladık.
Yöntem ve gereç: Tümör dışı nedenler ile ölen 116 erkek otopsi olgusunda alınan prostat dokularında PCa ve PIN
değerlendirildi. Olguların hepsi İstanbul’da yaşayan Türk vatandaşlarından oluşuyordu ve yaşları 40-79 arasında
değişmekte idi.
Bulgular: Tüm olguların % 19,8’inde PCa saptandı ve bunların dekatlara (5.-8.) göre dağılımı sırasıyla % 9,5, % 12,5, %
18,8 ve % 37’dir (P < 0,011). Yüksek dereceli (HG) PIN oranı dekatlara (5.-8.) dağılımı sırasıyla, % 33,3, % 31,3, % 56,3
and % 25,9’dur. PCa olgularının % 68,4’ünde eş zamanlı olarak HGPIN de saptandı. HGPIN ile PCa ve Gleason skoru
arasında istatistiksel olarak anlamlı ilişki saptandı (P < 0,002).
Sonuç: Türk toplumunda latent PCa sıklığı yüksek oranda (% 19,7)’dır. Latent PCa olgularını saptamak için, 40 yaş üstü
erkeklerin daha sıkı taranması gereklidir.
Anahtar sözcükler: Prostat kanseri, prostatik intraepitelyal neoplazi, prevalans, Türk erkekleri, otopsi
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Introduction
Prostatic carcinoma (PCa) is a public health problem
that is currently the most common neoplasm and
the second leading cause of cancer-related deaths in
males of western populations. Although it is more
commonly seen in males aged 64 and over, there has
been an increase in the frequency of PCa in people
under 50 years of age in recent years. This increase
has been attributed to a western-type diet and
widespread screening programs (1-6).
High-grade prostatic intraepithelial neoplasia
(HGPIN) is now accepted as the most likely preinvasive
stage of adenocarcinoma. Prostatic intraepithelial
neoplasia (PIN) has a high predictive value as a
marker for adenocarcinoma, and its identification
warrants repeat biopsy for concurrent or subsequent
invasive carcinoma. The only method of detection
is biopsy; PIN does not significantly elevate serum
prostate-specific antigen (PSA) concentration or its
derivatives, and it cannot be detected by ultrasound.
Most studies suggest that most patients with PIN will
develop carcinoma within 10 years (7-13).
PCa starts silently and may not be noticed until
the postmortem examination. The term “latent
PCa” is used to define PCa that is clinically silent
and determined during postmortem examination.
“Unsuspected” or “incidental PCa” refers to PCa
cases showing no abnormalities in the digital
rectal examination (DRE), routine PSA analysis, or
transrectal ultrasonography (5). Latent PCa cases
are found in autopsies (11,14-18), and unsuspected
PCa cases are generally incidentally detected in the
specimens of radical cystoprostatectomy (RCP) (1925) performed for bladder cancer or in the specimens
of prostatectomy and transurethral resection (TUR)
performed for nodular hyperplasia.
The majority of the epidemiologic studies
related to PCa and PIN are based on the biopsy
outcomes obtained from symptomatic patients
and PSA screenings (2,3,26,27). The specificity
and sensitivity of these studies in showing the
prevalence of PCa is lower than those of autopsy
studies (3,5,28-30). Therefore, it is thought that an
important group is present in the population (40%46%) with undiagnosed, clinically silent pathologies
of the prostatic gland. These cases are incidentally
detected, and the frequency of these lesions differs by
population (11,15-22).
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There is currently no study about the prevalence
of latent PCa in the Turkish population in either the
English or Turkish literature. The current study is the
first of its type. The aim of this study was to assess the
prevalence of latent PCa and PIN, their ranges within
decades, and their relationship with Gleason score.
Materials and methods
We examined prostate glands obtained from the
autopsies of 116 consecutive Turkish men, whose
autopsies were carried out at the Institute of Forensic
Medicine, İstanbul. In none of these 116 cases was the
cause of death cancer-related (Table 1). All prostate
glands were removed with the seminal vesicle and
Table 1. Causes of death in the studied cases.
Cause of death

n

%

Cardiovascular disease

35

36.5

Transportation fatalities

13

13.5

CO intoxication

7

7.3

Firearm fatalities

7

7.3

Mechanical asphyxia due to hanging

5

5.2

Respiratory failure resulting from pneumonia

4

4.2

Fall from great heights

4

4.2

Drowning

3

3.1

Work-related fatalities

3

3.1

Posttraumatic fat embolism

3

3.1

Blunt cranial trauma

3

3.1

Suicide by jumping from a bridge

2

2.1

Intracerebral bleeding (nontraumatic)

1

1.0

Mushroom poisoning

1

1.0

Complications related to cirrhosis

1

1.0

Tuberculosis

1

1.0

Stab wounds

1

1.0

Meningitis

1

1.0

Heroin intoxication

1

1.0

Total

96

100
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fixed in 10% neutral buffered formaldehyde. Of these
116 cases, 20 were excluded from the study due to
lack of clinical information and/or fixation error.

PCa

LG-PIN

HG-PIN

Percent (%)

56%

During the macroscopic examination, specimens
of prostate were cut into sections at intervals of 0.5
cm, and the cut surfaces were examined. A total of
7-11 specimens (average: 9) were taken from every
gland. All of the blocks obtained were embedded in
paraffin, sectioned to produce 5-μm whole-mount
sections, and stained with hematoxylin and eosin.
During the microscopic examination, specimens
were analyzed for the presence of PCa and PIN.
Gleason scoring was used to grade the PCa. PIN
cases were subdivided into categories of low grade or
high grade.

37%
33%

31%
26% 26%
19%

19%
13% 13%

10%

5

13%

7

6

8

Decade

Figure 1. Percentage of prostate carcinoma [PCa] cases and
low-grade and high-grade prostatic intraepithelial
neoplasia (LGPIN and HGPIN, respectively) by
decade.

patients under 50 years of age, 15% of patients aged
50-65, and 31.4% of patients over 65. Among the PCa
cases, 2 patients were under 50 years of age (10.5%),
6 patients (31.6%) were between 50 and 65, and 11
patients (57.9%) were over 65 years. Of the 19 PCa
cases detected, 11 (58%) were well differentiated and
8 (42%) were moderately differentiated. There were
no poorly differentiated PCa cases in this series.

For statistical evaluation, the range of PCa
according to decade and the relationship between
PIN and Gleason score were calculated by the Pearson
correlation method using SPSS 12.0.
Results
The age distribution of the patients ranged between
40 and 79 (mean: 59.6, median: 58). The number
of patients in decades 5-8 was 21, 32, 16, and 27,
respectively. Of these patients, 21.8% were under 50,
41.7% were between 50 and 65, and 36.5% were over
65 years old.

PIN was detected in 50 cases (52%). Of these
PIN cases, 33 (34.4%) were HGPIN and 17 (17.7%)
were low-grade prostatic intraepithelial neoplasia
(LGPIN). The frequency of HGPIN by decade was
33%, 31%, 56%, and 26%, respectively, for decades
5-8 (Figure 1). Relatively more cases of HGPIN were
found in decades 7 and 8 (Table 2). There was no
statistically significant relationship between HGPIN
and LGPIN by decade (P > 0.05).

PCa was detected in 19 (19.8%) of a total 96 cases.
The prevalence of PCa by decade was 9.5%, 12.5%,
18.8%, and 37%, respectively, for decades 5-8 (P
< 0.011) (Table 2, Figure 1). A linear relationship
was found between PCa and decade (Figure 2). The
patients were grouped as follows: under 50, 50-65,
and over 65 years old. PCa was detected in 9.5% of

PIN was detected in 14 out of a total of 19 PCa
cases (74%). Of these cases, 13 (93%) were HGPIN.
PIN was detected in 36 (47%) of a total 77 nodular

Table 2. Range of PCa and PIN according to decades.
Decades
Total

P-value

5 (%)

6 (%)

7 (%)

8 (%)

21

32

16

27

96

PCa

2 (9.5)

4 (12.5)

3 (18.8)

10 (37)

19

0.009

LGPIN

4 (19)

4 (12.5)

2 (12.5)

7 (25.9)

17

0.176

HGPIN

7 (33.3)

10 (31.3)

9 (56.3)

7 (25.9)

33

0.911

n
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Figure 2. Cumulative frequency of PCa and PIN by decade.

hyperplasia cases, and, among these PIN cases, 20
(26%) were HGPIN and 16 (21%) were LGPIN. Linear
relationships among the PIN, PCa, and Gleason
score were found (Figures 3 and 4). Although there
was a statistically highly significant correlation of
HGPIN with PCa and Gleason score (P < 0.002), it
was not significant in terms of the relation to decade
(P > 0.05). There was a strong negative correlation
between HGPIN and nodular hyperplasia (P < 0.006).
Discussion
Prostate cancer is the second most frequently
diagnosed cancer in men (903,000 new cases, 13.6%
of the total) and the fifth most common cancer
overall. Nearly three-fourths of the registered cases
occur in developed countries (648,000 cases).
Incidence rates of prostate cancer vary by more than
25-fold worldwide; the highest rates are in Australia
and New Zealand (104.2 per 100,000), western and
northern Europe, and North America. Incidence
rates are also relatively high in certain developing
452

Ca (-)

Ca (+)
Prostate carcinoma

Figure 3. The linear relation between PCa and LGPIN and
HGPIN.

regions such as the Caribbean, South America, and
sub-Saharan Africa. The lowest age-standardized
incidence rate (ASR) is estimated to be that of southcentral Asia (4.1 per 100,000). Turkey belongs to the
group of low-incidence (14.8 per 100,000) countries.
The difference between high- and low-incidence
regions varies between 30-fold and 400-fold (31).
With an estimated 258,000 deaths in 2008, prostate
cancer is the sixth leading cause of cancer death in
men (6.1% of the total). Because PSA testing has a
much greater impact on incidence than on mortality,
there is less variation in mortality rates worldwide
(10-fold) than in incidence rates (25-fold), and the
number of deaths from prostate cancer is almost the
same in developed and developing regions. Mortality
rates are generally high in predominantly black
populations (Caribbean, ASR of 26.3 per 100,000;
sub-Saharan Africa, ASR of 18-19 per 100,000),
very low in Asia (ASR of 2.5 per 100,000 in eastern
Asia, for example), and intermediate in Europe and
Oceania (31).
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intake. Widespread use of PSA screening has resulted
in the detection of PCa cases in the early stages. As
a result of the above factors, an increase in radical
prostatectomy cases of up to 40% and an increase in
tumors of T1 grade in individuals younger than 60
have been reported (3,5,29,33-36).

50

LGPIN
HGPIN

Cumulative frequency

40

30

20

1.00

2.00

3.00

4.00

5.00

6.00

7.00

Gleason score

Figure 4. Cumulative frequency of
Gleason scor

LGPIN and HGPIN by

Migration studies show that men moving from
Japan and China to the US adopt an increased risk
of prostate cancer. Second and third-generation
Japanese Americans and Chinese Americans actually
have a prostate cancer risk level similar to that of
white American men. This suggests that environment
has an influence on prostate cancer (5,32).
The geographical distribution of PCa differs, and,
even within the same country, there is a significant
difference in terms of incidence and mortality in
individuals of different races. PCa is seen more
frequently (2-fold) in blacks than whites, and the
mortality rate is also higher among blacks (1-5,3133).
It has been reported that there has been a
significant increase in the incidence of PCa worldwide
in the past 30 years (2-5,29,33-35). This increase is
attributed to the widespread use of PSA screenings,
the aging of the population, and excessive caloric

In autopsy and RCP studies, PCa that is clinically
silent and undetected in routine screenings has
been found at high rates. Although the PCa rates
detected in these studies differ, the outcomes of RCP
cases are higher than those of autopsy cases. The
frequency of PCa in autopsy studies was reported to
range between 18% and 39% (average: 27%) (11,1418); it ranged between 4% and 70% (average: 34%)
in RCP studies (19-25,37,38). The frequency of
incidentally discovered PCa in cystoprostatectomy
specimens is extremely variable because of several
factors, particularly the pathology sampling. The
rate of clinically detectable PCa in men with bladder
cancer was 19-fold greater than expected. It has been
proposed that the high incidence of prostate and
bladder cancer occurring together can be explained
by a common carcinogenic pathway (19-24).
Kurokawa et al. (37) reported that the detection rate
of PCa was 12.5% and 1.5% in bladder cancer cases
and control cohorts, respectively. This finding shows
that PCa incidence studies carried out in RCP cases
may be misleading for detection of PCa incidence.
For this reason, PCa data obtained from autopsy
studies become more important.
Stemmermann et al. (15) reported prostate cancer
in 27% of autopsied Hawaiian Japanese men who
died after 50 years of age, reaching a frequency of 63%
among men over 80 years of age. The volume of 60%
of these cancers was less than 150 mm3. These small
tumors would probably not have been discovered in
a screening program. Tumors larger than 1000 mm3
would probably have been discovered using modern
diagnostic procedures, but were found in only 4.4%
of the autopsied men. These data show that there is a
significant difference between the incidence of PCa
detected in the community and the real incidence of
PCa (38).
Although PCa is commonly seen in men over 65
years of age, the increase in the number of cases in
those under 50 years of age in recent years is striking.
The incidence of PCa increases with age in a linear
453

Prevalence of latent PCa and PIN

manner (3-5,10-12,14,29,30). PCa is diagnosed in
30% of men in decade 4 of life, in 50% of those under
50 years old, and in 75% of those over 85 years old.
Familial PCa cases generally emerge at earlier ages
(1,4).
In an autopsy study carried out in Spain, SanchezChapado et al. (14) reported the prevalence of PCa as
3.58%, 8.82%, 14.28%, 23.8%, 31.7%, and 33.33% in
decades 3-8, respectively. In our study, the prevalence
of PCa was 9.5%, 12.5%, 19%, and 37% in decades
5-8, respectively. The prevalence of PCa in decades 6
and 7 in the Spanish population was approximately 2
times higher than in the population from our study.
However, the prevalence rate in decade 8 was slightly
higher in our population (37%).
The incidence of HGPIN ranges between 29% and
85% in different studies. The most important reason
for this great variation is the fact that HGPIN rates
differ in different populations (8,10,11,14,39). Desai
et al. (8), Fujita et al. (39), and Sanchez-Chapado et
al. (14) reported rates of HGPIN at 85%, 51%, and
29% in India, Japan, and Spain, respectively. Our
study found a rate of 34% in the Turkish population.
While the coincidence of HGPIN with nodular
hyperplasia is 4%-18%, the coincidence of HGPIN
and PCa ranges between 33% and 100% (average:
70%) (8,11,14,21,25,26,30). In this study, we detected
HGPIN in 68.4% of PCa cases and 26% of nodular
hyperplasia cases. There was a statistically significant
correlation between HGPIN and PCa (P < 0.002).
The distribution and/or extent of HGPIN
correlates with the age of the patient, prostate
cancer stage, and grade and volume (9,10). SanchezChapado et al. (14) reported a statistically significant
association between tumor dimension and pathologic
stage, but they found no such association among
PSA level, Gleason score, and patient age. We found
a statistically significant association between HGPIN
and tumor grade (P = 0.002), but not with age (P >
0.05).
HGPIN prevalence differs in different racial
groups living in the same country. In the US, the
prevalence of HGPIN in blacks is 2 times higher than
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that in whites, just as with PCa (10). Sakr et al. (12)
found that HGPIN starts in young individuals and
increases progressively with advancing age in both
whites and blacks, but is more prevalent in African
Americans. Additionally, the more extensive form of
HGPIN, with multifocal or diffuse involvement of the
gland, appears at a younger age in African Americans.
The finding that HGPIN is more prevalent in African
Americans and that the more diffuse form appears
earlier in this same group indicates a potentially
important role for this lesion in the race-related
discrepancies associated with this disease.
The frequency of poorly differentiated tumors has
decreased due to an increase in the number of cases
diagnosed early. Perotti et al. (36), comparing US data
from 1980-1984 and 1990-1994, reported a decrease
in the number of grade 3 PCa cases (24.4% versus
21.4%), a decrease in metastasis rates (33.1% versus
17.4%), and an increase in the number of patients
undergoing radical prostatectomy or radiotherapy.
Frequency of PCa increased with increasing age,
but the mortality rate was inversely related to age, as
indicated by 30% mortality in those younger than
60 years old, 24% in those between 60 and 70 years
old, and 7.5% in those over 70 years. Among those
with carcinoma, 83% died of other unrelated causes;
of those who died, 80% had poorly differentiated
(grade 3 or 4) tumors. Given the indolent biological
nature of well-differentiated tumors in those older
than 70 years, PCa should not, in most instances,
be regarded as a life-threatening diagnosis, with or
without treatment, in older individuals. The tumor
seems to be biologically more aggressive in younger
men, especially those younger than 60 years (16).
In conclusion, autopsy studies show that, despite
the widespread use of screening programs, there is
still an asymptomatic PCa group in the community at
a rate of 20%-26%. The current screening programs
must be used more, and the diagnostic methods must
be further developed in order to detect this patient
group. The strong correlation between HGPIN and
PCa confirms these lesions as a preinvasive stage of
PCa.
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